|
Synonyms: AZD8895 | COV2-2196 | Evusheld® (tixagevimab + cilgavimab)
tixagevimab is an approved drug (EMA (2022))
Compound class:
Antibody
Comment: Tixagevimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [2]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. Tixagevimab is designed to be a long-acting agent, and in combination with cilgavimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1]. AstraZeneca have reported that Evusheld® retains neutralising activity against the omicron (B.1.1.529) SARS-CoV-2 variant.
|
| No information available. |
Summary of Clinical Use  |
| In clinical evaluation for COVID-19 in the mAb cocktail AZD7442 (trade named Evusheld®; tixagevimab (AZD8895) + cilgavimab (AZD1061). These two mAbs have non-overlapping epitopes on the SARS-CoV-2 spike protein [1]. AZD7442 was evaluated as pre- and post-exposure prophylaxis of COVID-19 in adults. Evusheld® was granted FDA EUA for pre-exposure prophylaxis of COVID-19 in late 2021. However as the pattern of globally circulating variants evolved in mid-late 2022, Evusheld's efficacy was severly compromised, and in January 2023 the FDA withdrew the EUA. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04507256 | AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19 | Phase 1 Interventional | AstraZeneca | ||
| NCT04625725 | Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. | Phase 3 Interventional | AstraZeneca | In August 2021 AstraZeneca announced that AZD7442 met its primary endpoint in this study (the PROVENT trial), reducing the risk of developing symptomatic COVID-19 by 77% [...]. There were no cases of severe COVID-19 or COVID-19-related deaths in the AZD7442 treatment arm; 2 of 3 people in the placebo group who contracted COVID-19 died, the third developed severe disease. | |
| NCT04625972 | Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults | Phase 3 Interventional | AstraZeneca | AstraZeneca have announced that AZD7442 failed to improve outcomes when administered shortly after exposure to SARS-CoV-2. | |
| External links |
|
For extended ADME data see the following: Drugs.com |
